/**
 * FDA companion diagnostic rows that the readouts in biomarker-readouts*.ts did not yet carry, one per device, indication and
 * drug as the FDA list prints them (FDA_CDX_URL, read 2026-11-03). Each row is attached to the readout it selects for
 * and merged onto that record in src/data/index.ts after the readout's own rows; a row the readout already holds (same
 * device, PMA number and drugs) is not added twice.
 *
 * Found by the cdx-fda denominator on /completeness/ (scripts/fetch-universe-regulatory.ts, src/lib/completeness.ts).
 * Three oncology rows have no readout in OnCo to attach to and stay listed there as gaps: the Dako EGFR pharmDx Kit
 * (EGFR protein expression, cetuximab and panitumumab in colorectal cancer), the ARUP PDGFRB FISH Assay (imatinib in
 * myelodysplastic or myeloproliferative disease) and the Cytocell KMT2A Breakapart FISH Probe Kit (revumenib in acute
 * leukaemia).
 */
import type { CompanionDiagnostic } from "@/lib/schema";
import { cdx } from "./biomarker-readouts";

export const CDX_FDA_ROWS: Record<string, CompanionDiagnostic[]> = {
  "alk-fusion": [
    cdx("Ventana ALK (D5F3) CDx Assay", "Ventana Medical Systems, Inc.", "Non-Small Cell Lung Cancer (NSCLC) - Tissue", ["crizotinib"], "P140025 (06/12/2015)"),
    cdx("Ventana ALK (D5F3) CDx Assay", "Ventana Medical Systems, Inc.", "Non-Small Cell Lung Cancer (NSCLC) - Tissue", ["ceritinib"], "P140025/S005 (05/26/2017)"),
    cdx("Vysis ALK Break Apart FISH Probe Kit", "Abbott Molecular Inc.", "Non-Small Cell Lung Cancer (NSCLC) - Tissue", ["brigatinib"], "P110012/S020 (05/22/2020)", "abbott"),
    cdx("FoundationOne CDx", "Foundation Medicine Inc.", "Non-Small Cell Lung Cancer (NSCLC) - Tissue", ["brigatinib"], "P170019/S023 (06/30/2021)", "foundation-medicine"),
  ],
  "braf-v600e": [
    cdx("Guardant360® Liquid CDx", "Guardant Health, Inc.", "Colorectal cancer - Plasma", ["encorafenib"], "P250027 (05/19/2026)", "guardant-health"),
    cdx("FoundationOne CDx", "Foundation Medicine, Inc.", "Non-Small Cell Lung Cancer (NSCLC) - Tissue", ["dabrafenib","trametinib"], "P170019 (11/30/2017)", "foundation-medicine"),
    cdx("FoundationOne CDx", "Foundation Medicine, Inc.", "Melanoma - Tissue", ["trametinib"], "P170019 (11/30/2017)", "foundation-medicine"),
    cdx("FoundationOne CDx", "Foundation Medicine, Inc.", "Melanoma - Tissue", ["atezolizumab","cobimetinib","vemurafenib"], "P170019/S030 (01/19/2022)", "foundation-medicine"),
    cdx("FoundationOne Liquid CDx", "Foundation Medicine, Inc.", "Non-Small Cell Lung Cancer (NSCLC) - Plasma", ["encorafenib","binimetinib"], "P190032/S011 (10/11/2023)", "foundation-medicine"),
    cdx("FoundationOne Liquid CDx", "Foundation Medicine, Inc.", "Metastatic Colorectal Cancer (mCRC) - Plasma", ["encorafenib"], "P190032/S010 (06/08/2023)", "foundation-medicine"),
    cdx("MI Cancer Seek (MCS)", "Caris Life Sciences", "Colorectal Cancer - Tissue", ["encorafenib","cetuximab"], "P240010 (11/05/2024)", "caris"),
    cdx("MI Cancer Seek (MCS)", "Caris Life Sciences", "Melanoma - Tissue", ["trametinib"], "P240010 (11/05/2024)", "caris"),
    cdx("PGDx elio tissue complete CDx", "Personal Genome Diagnostics, Inc.", "Melanoma - Tissue", ["dabrafenib","vemurafenib","cobimetinib","encorafenib","binimetinib","trametinib"], "P250036 (7/30/2026)"),
    cdx("MI Cancer Seek", "Caris Life Sciences", "Melanoma - Tissue", ["dabrafenib","vemurafenib"], "P240010 (11/05/2024)", "caris"),
    cdx("MI Cancer Seek", "Caris Life Sciences", "Melanoma - Tissue", ["cobimetinib","vemurafenib","encorafenib","binimetinib","dabrafenib","trametinib"], "P240010 (11/05/2024)", "caris"),
  ],
  "brca-germline": [
    cdx("BRACAnalysis CDx", "Myriad Genetic Laboratories, Inc.", "Ovarian Cancer - Whole Blood", ["rucaparib"], "P140020/S016 (10/16/2018)", "myriad-genetics"),
  ],
  "brca-somatic": [
    cdx("FoundationOne CDx", "Foundation Medicine, Inc.", "Prostate Cancer - Tissue", ["niraparib","abiraterone"], "P170019/S042 (08/11/2023)", "foundation-medicine"),
    cdx("FoundationOne Liquid CDx", "Foundation Medicine, Inc.", "Metastatic Castrate Resistant Prostate Cancer (mCRPC) - plasma", ["niraparib","abiraterone"], "P190032/S014 (06/28/ 2024)", "foundation-medicine"),
    cdx("FoundationOne Liquid CDx", "Foundation Medicine, Inc.", "Metastatic Castrate Resistant Prostate Cancer (mCRPC) - Plasma", ["olaparib"], "P190032/S016 (08/30/2024)", "foundation-medicine"),
    cdx("FoundationOne Liquid CDx", "Foundation Medicine, Inc.", "Metastatic Castrate Resistant Prostate Cancer (mCRPC) - Plasma", ["olaparib"], "P200016 (11/06/2020)", "foundation-medicine"),
  ],
  "egfr-exon-19-deletion": [
    cdx("Guardant360® Liquid CDx", "Guardant Health, Inc.", "Non-small cell lung cancer (NSCLC) - Plasma", ["osimertinib"], "P250027 (05/19/2026)", "guardant-health"),
    cdx("therascreen EGFR RGQ PCR Kit", "Qiagen Manchester, Ltd.", "Non-Small Cell Lung Cancer (NSCLC) - Tissue", ["gefitinib"], "P120022/S001 (07/10/2015)", "qiagen"),
    cdx("ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA)", "Pillar Biosciences, Inc.", "Non-Small Cell Lung Cancer (NSCLC) - Tissue", ["erlotinib","osimertinib","gefitinib","afatinib","dacomitinib","lazertinib"], "P200011 (07/30/2021)"),
    cdx("MI Cancer Seek", "Caris Life Sciences", "Non-Small Cell Lung Cancer (NSCLC) - Tissue", ["erlotinib","osimertinib","gefitinib","afatinib","dacomitinib","lazertinib"], "P240010 (11/05/2024)", "caris"),
  ],
  "egfr-exon-20-insertion": [
    cdx("Guardant360® Liquid CDx", "Guardant Health, Inc.", "Non-small cell lung cancer (NSCLC) - Plasma", ["amivantamab"], "P250027 (05/19/2026)", "guardant-health"),
  ],
  "esr1-mutation-ctdna": [
    cdx("Guardant360 CDx", "Guardant Health, Inc.", "Breast Cancer - Plasma", ["camizestrant"], "P200010/S024 (09/04/2026)", "guardant-health"),
    cdx("Guardant360 CDx", "Guardant Health, Inc.", "Breast Cancer - Plasma", ["vepdegestrant"], "P200010/S025 (05/01/2026)", "guardant-health"),
    cdx("Guardant360® Liquid CDx", "Guardant Health, Inc.", "Breast cancer - Plasma", ["elacestrant"], "P250027 (05/19/2026)", "guardant-health"),
    cdx("Guardant360® Liquid CDx", "Guardant Health, Inc.", "Breast Cancer - Plasma", ["imlunestrant"], "P250027 (05/19/2026)", "guardant-health"),
  ],
  "ezh2-y646-mutation": [
    cdx("cobas EZH2 Mutation Test", "Roche Molecular Systems, Inc.", "Follicular Lymphoma Tumor - Tissue", ["tazemetostat"], "P200014 (06/18/2020)"),
  ],
  "her2-ihc-3-plus": [
    cdx("HercepTest", "Dako Denmark A/S", "Breast Cancer - Tissue", ["pertuzumab"], "P980018/S015 (06/08/2012)", "agilent"),
    cdx("HercepTest", "Dako Denmark A/S", "Breast Cancer - Tissue", ["trastuzumab-emtansine"], "P980018/S016 (02/22/2013)", "agilent"),
    cdx("InSite Her-2/neu (CB11) Monoclonal Antibody", "Biogenex Laboratories, Inc.", "Breast Cancer - Tissue", ["trastuzumab"], "P040030 (12/22/2004)"),
    cdx("PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody", "Ventana Medical Systems, Inc.", "Breast Cancer - Tissue", ["trastuzumab-emtansine"], "P990081/S039 (05/03/2019)"),
  ],
  "her2-ish-amplified": [
    cdx("VENTANA HER2 Dual ISH DNA Probe Cocktail", "Ventana Medical Systems, Inc.", "Gastroesophageal adenocarcinoma (GEA: gastric, gastroesophageal junction, and esophageal adenocarcinoma)", ["zanidatamab"], "P190031/S016 (08/25/2026)"),
    cdx("FoundationOne CDx", "Foundation Medicine, Inc.", "Breast Cancer - Tissue", ["trastuzumab"], "P170019 (11/30/2017)", "foundation-medicine"),
    cdx("FoundationOne CDx", "Foundation Medicine, Inc.", "Breast Cancer - Tissue", ["pertuzumab"], "P170019 (11/30/2017)", "foundation-medicine"),
    cdx("FoundationOne CDx", "Foundation Medicine, Inc.", "Breast Cancer - Tissue", ["trastuzumab-emtansine"], "P170019 (11/30/2017)", "foundation-medicine"),
    cdx("HER2 CISH pharmDx Kit", "Dako Denmark A/S", "Breast Cancer - Tissue", ["trastuzumab"], "P100024 (11/30/2011)", "agilent"),
    cdx("HER2 FISH pharmDx Kit", "Dako Denmark A/S", "Breast Cancer - Tissue", ["pertuzumab"], "P040005/S006 (06/08/2012)", "agilent"),
    cdx("HER2 FISH pharmDx Kit", "Dako Denmark A/S", "Breast Cancer - Tissue", ["trastuzumab-emtansine"], "P040005/S009 (02/22/2013)", "agilent"),
    cdx("INFORM HER-2/neu", "Ventana Medical Systems, Inc.", "Breast Cancer - Tissue", ["trastuzumab"], "P940004 (12/30/1997)"),
    cdx("SPOT-LIGHT HER2 CISH Kit", "Life Technologies Corporation", "Breast Cancer - Tissue", ["trastuzumab"], "P050040 (07/01/2008)", "thermo-fisher"),
  ],
  "her2-mutation": [
    cdx("Oncomine Dx Express Test", "Life Technologies Corporation", "Non-Small Cell Lung Cancer (NSCLC) - Tissue", ["sevabertinib"], "P240040/S005 (09/09/2026)", "life-technologies"),
    cdx("Guardant360® Liquid CDx", "Guardant Health, Inc.", "Non-small cell lung cancer (NSCLC) - Plasma", ["trastuzumab-deruxtecan"], "P250027 (05/19/2026)", "guardant-health"),
    cdx("Oncomine Dx Target Test", "Life Technologies Corporation", "Non-Small Cell Lung cancer (NSCLC) - Tissue", ["sevabertinib"], "P160045/S050 (11/19/2025)", "thermo-fisher"),
  ],
  "hrr-gene-mutation": [
    cdx("FoundationOne Liquid CDx", "Foundation Medicine, Inc.", "Metastatic Castrate Resistant Prostate cancer (mCRPC)-Plasma", ["talazoparib","enzalutamide"], "P190032/S029 (05/27/2026)", "foundation-medicine"),
  ],
  "kras-g12c": [
    cdx("Guardant360® Liquid CDx", "Guardant Health, Inc.", "Non-small cell lung cancer (NSCLC) - Plasma", ["sotorasib"], "P250027 (05/19/2026)", "guardant-health"),
  ],
  "met-ex14": [
    cdx("FoundationOne Liquid CDx", "Foundation Medicine, Inc.", "Non-Small Cell Lung Cancer (NSCLC) - Plasma", ["tepotinib"], "P190032/S015 (11/14/2024)", "foundation-medicine"),
  ],
  "pik3ca-hotspot-mutation": [
    cdx("FoundationOne CDx", "Foundation Medicine, Inc.", "Breast Cancer - Plasma", ["inavolisib"], "P170019/S062 (05/27/2026)", "foundation-medicine"),
    cdx("FoundationOne Liquid CDx", "Foundation Medicine, Inc.", "Breast Cancer - Plasma", ["alpelisib"], "P200006 (10/26/2020)", "foundation-medicine"),
    cdx("MI Cancer Seek (MCS)", "Caris Life Sciences", "Breast Cancer - Tissue", ["alpelisib"], "P240010 (11/05/2024)", "caris"),
  ],
  "ras-wild-type": [
    cdx("cobas KRAS Mutation Test", "Roche Molecular Systems, Inc.", "Colorectal Cancer - Tissue", ["cetuximab"], "P140023 (05/07/2015)"),
    cdx("cobas KRAS Mutation Test", "Roche Molecular Systems, Inc.", "Colorectal Cancer - Tissue", ["panitumumab"], "P140023 (05/07/2015)"),
    cdx("xT CDx", "Tempus Labs, Inc.", "Colorectal Cancer (CRC) - Tissue (Matching Blood/Saliva)", ["cetuximab"], "P210011 (04/28/2023)", "tempus"),
    cdx("xT CDx", "Tempus Labs, Inc.", "Colorectal Cancer (CRC) - Tissue (Matching Blood/Saliva)", ["panitumumab"], "P210011 (04/28/2023)", "tempus"),
  ],
};
